Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney

BACKGROUND: Excess body burden of uric acid promotes gout. Diminished renal clearance of uric acid causes hyperuricemia in most patients with gout, and the renal urate transporter (URAT)1 is important for regulation of serum uric acid (sUA) levels. The URAT1 inhibitors probenecid and benzbromarone a...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Arthritis Res Ther
Main Authors: Miner, Jeffrey, Tan, Philip K., Hyndman, David, Liu, Sha, Iverson, Cory, Nanavati, Payal, Hagerty, David T., Manhard, Kimberly, Shen, Zancong, Girardet, Jean-Luc, Yeh, Li-Tain, Terkeltaub, Robert, Quart, Barry
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2016
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5048659/
https://ncbi.nlm.nih.gov/pubmed/27716403
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-016-1107-x
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki